An observational study in Macrophage Activation Syndrome, Still's Disease, Adult-Onset and Stills Disease, Juvenile-Onset, sponsored by Swedish Orphan Biovitrum. Completed at 11 sites in 7 countries. Open to participants aged 6 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Swedish Orphan Biovitrum · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.
20 studies on the registry are indexed under Macrophage Activation Syndrome; 4 are open to participants now.
Browse Macrophage Activation Syndrome studies →Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will include patients with Still's disease who were diagnosed with MAS that was refractory to GC treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Retrospective Chart Review
Overall survival
The proportion of patients alive after 1-year of follow-up
Time frame: 1 year
Time to laboratory value normalization
Time to normalization for the key laboratory values
Time frame: From Index date up to 26 weeks
Time to Macrophage Activation Syndrome (MAS) laboratory remission
Time to normalization for all key laboratory values
Time frame: From Index date up to 26 weeks
Time to partial MAS laboratory remission
Time to normalization for at least 3 key laboratory values
Time frame: From Index date up to 26 weeks
Time to tapering of Glucocorticoids (GCs)
From index date to the last of 7 consecutive days receiving ≤1 mg/kg/day of prednisone (PDN).
Time frame: from index date to the last of 7 consecutive days
Number of recurrent MAS episodes
Occurring any time after the end of the data collection period for the index MAS episode
Time frame: through study completion
Administration of organ support care
Proportion of patients receiving hemodialysis, assisted ventilation, cardiac support, or inotropic drugs
Time frame: from the index date until either the end of hospitalization or 26 weeks, whichever occurs later
Characteristics of MAS treatment
description of treatment patterns of MAS-related treatments for both index and recurrent MAS episodes.
Time frame: for MAS episodes occurring during the data collection period
Clinical signs
No of MAS symptoms (Fever, Skin rash, Hemorrhagic manifestations, Evidence of CNS involvement) present
Time frame: At index date and 8 weeks after index date or at the earliest time this data becomes available between 8 and 12 weeks
Time to hospital discharge
Defined as time from the index date to discharge from the hospital
Time frame: Up to 26 weeks
Time to intensive care unit (ICU) discharge
For patients who are admitted to the ICU during the index MAS episode, this is defined as time from index date or ICU admission (whichever comes later) to ICU discharge
Time frame: Up to 26 weeks
Duration of Clinical Response
defined as the time (in days) from the date of first documented MAS laboratory remission until the date of first documented occurrence of a new MAS episode as per investigator's assessment.
Time frame: Until week 26
Ran from Sep 2023 to primary completion in Sep 2024, 11 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Macrophage Activation Syndrome →